# | Title | Journal | Year | Citations |
---|
1 | The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 12,681 |
2 | The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 7,498 |
3 | Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 5,550 |
4 | National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Alzheimer's and Dementia | 2012 | 1,968 |
5 | Introduction to the recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Alzheimer's and Dementia | 2011 | 1,547 |
6 | Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population‐based perspective | Alzheimer's and Dementia | 2015 | 1,187 |
7 | Neuropsychiatric symptoms in Alzheimer's disease | Alzheimer's and Dementia | 2011 | 752 |
8 | Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup | | 2011 | 531 |
9 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers | Lancet Neurology, The | 2017 | 464 |
10 | Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association | Alzheimer's and Dementia | 2013 | 443 |
11 | Consensus classification of posterior cortical atrophy | Alzheimer's and Dementia | 2017 | 423 |
12 | Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting | Alzheimer's and Dementia | 2013 | 418 |
13 | Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia | JAMA - Journal of the American Medical Association | 2019 | 391 |
14 | Research priorities to reduce the global burden of dementia by 2025 | Lancet Neurology, The | 2016 | 284 |
15 | World‐Wide FINGERS Network: A global approach to risk reduction and prevention of dementia | Alzheimer's and Dementia | 2020 | 257 |
16 | Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias | Lancet Neurology, The | 2020 | 254 |
17 | White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2019 | 250 |
18 | Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association | Journal of Nuclear Medicine | 2013 | 248 |
19 | Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2017 | 240 |
20 | Brain Health: The Importance of Recognizing Cognitive Impairment: An IAGG Consensus Conference | Journal of the American Medical Directors Association | 2015 | 222 |
21 | Down syndrome and Alzheimer's disease: Common pathways, common goals | Alzheimer's and Dementia | 2015 | 218 |
22 | New insights into atypical Alzheimer's disease in the era of biomarkers | Lancet Neurology, The | 2021 | 214 |
23 | Guidelines for the standardization of preanalytic variables for blood‐based biomarker studies in Alzheimer's disease research | Alzheimer's and Dementia | 2015 | 205 |
24 | The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease | Alzheimer's and Dementia | 2022 | 169 |
25 | Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease | Alzheimer's and Dementia | 2018 | 163 |
26 | The chronic neuropsychiatric sequelae of COVID‐19: The need for a prospective study of viral impact on brain functioning | Alzheimer's and Dementia | 2021 | 140 |
27 | Developing novel blood‐based biomarkers for Alzheimer's disease | Alzheimer's and Dementia | 2014 | 138 |
28 | Alzheimer’s Association Dementia Care Practice Recommendations | Gerontologist, The | 2018 | 133 |
29 | Vascular contributions to cognitive impairment and dementia (VCID): A report from the 2018 National Heart, Lung, and Blood Institute and National Institute of Neurological Disorders and Stroke Workshop | Alzheimer's and Dementia | 2020 | 108 |
30 | Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 104 |
31 | Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease | Alzheimer's and Dementia | 2013 | 100 |
32 | The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable | Alzheimer's and Dementia | 2018 | 98 |
33 | Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome | Alzheimer's and Dementia | 2017 | 94 |
34 | Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease | Alzheimer's and Dementia | 2016 | 93 |
35 | The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions | Alzheimer's and Dementia | 2016 | 91 |
36 | Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education | Alzheimer's and Dementia | 2013 | 90 |
37 | Measuring cognition and function in the preclinical stage of Alzheimer's disease | Alzheimer's and Dementia: Translational Research and Clinical Interventions | 2018 | 87 |
38 | Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group | Alzheimer's and Dementia | 2022 | 84 |
39 | Optimizing Coding and Reimbursement to Improve Management of Alzheimer's Disease and Related Dementias | Journal of the American Geriatrics Society | 2002 | 83 |
40 | Caregiver Outcomes of Partners in Dementia Care: Effect of a Care Coordination Program for Veterans with Dementia and Their Family Members and Friends | Journal of the American Geriatrics Society | 2013 | 82 |
41 | Revolutionizing Alzheimer's disease and clinical trials through biomarkers | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring | 2015 | 80 |
42 | Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease | Alzheimer's and Dementia | 2014 | 77 |
43 | Assessment of cognition in early dementia | Alzheimer's and Dementia | 2011 | 75 |
44 | Assessing cognition and function in Alzheimer's disease clinical trials: Do we have the right tools? | Alzheimer's and Dementia | 2014 | 73 |
45 | Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions | Nature Reviews Neurology | 2015 | 65 |
46 | The case for low-level BACE1 inhibition for the prevention of Alzheimer disease | Nature Reviews Neurology | 2021 | 65 |
47 | 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease | | 2014 | 64 |
48 | Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans | Alzheimer's and Dementia | 2014 | 56 |
49 | Building a roadmap for developing combination therapies for Alzheimer’s disease | Expert Review of Neurotherapeutics | 2015 | 54 |
50 | The Public Health Road Map to Respond to the Growing Dementia Crisis | Innovation in Aging | 2020 | 54 |